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Introduction {#sec005}
============

Choledocholithiasis, or common bile duct (CBD) stones, is a common disease globally. Endoscopic retrograde cholangiopancreatography (ERCP) with biliary endoscopic sphincterotomy (EST) has become the preferred therapeutic procedure for CBD stone removal. Endoscopic papillary balloon dilation (EPBD) was developed as a comparable alternative method to EST since the 1990s \[[@pone.0233388.ref001], [@pone.0233388.ref002]\]. Because of a lower risk of bleeding and preservation of papillary function \[[@pone.0233388.ref003]\], EPBD is comparable to EST for stone extraction, though it may require more endoscopic mechanical lithotripsy (EML) \[[@pone.0233388.ref004]--[@pone.0233388.ref006]\]. Furthermore, EPBD is usually preferred in younger patients or patients with coagulopathy \[[@pone.0233388.ref007], [@pone.0233388.ref008]\].

However, the biggest concern of EPBD is the increased rate of post-ERCP pancreatitis (PEP) \[[@pone.0233388.ref004], [@pone.0233388.ref005], [@pone.0233388.ref009], [@pone.0233388.ref010]\]. Some studies have found that the duration of EPBD was inversely associated with the risk of PEP \[[@pone.0233388.ref011]\]. However, the adequate dilatation time is still unclear. A randomized trial by Liao et al. found that the risk of PEP was lower with a 5-minute EPBD than with a 1-minute EPBD (4.8% vs. 15.1%), with a relative risk of 0.32 \[[@pone.0233388.ref012]\]. Chan et al. performed large balloon dilatations alone without sphincterotomy in 247 patients with large CBD stones. The mean duration of the dilatation procedure was 4.7 minutes, and the PEP rate was 0.8% (2/247) \[[@pone.0233388.ref013]\]. Oh et al. compared endoscopic papillary large balloon dilatation (EPLBD) and EST for removal of large CBD stones, with a duration of balloon dilatation of 31.3 seconds and a PEP rate of 5.0% \[[@pone.0233388.ref014]\]. Additionally, a meta-analysis showed that short EPBD (≤1 minute) had a higher risk of pancreatitis (odds ratio, 3.87) \[[@pone.0233388.ref011]\]. Currently, it is understood that balloon dilatation ≤1 minute actually increases the risk of pancreatitis in patients with CBD stones less than 1 cm \[[@pone.0233388.ref011], [@pone.0233388.ref012]\]. A compartment syndrome from post-EPBD hemorrhage/edema with uncut Sphincter of Oddi has been the proposed mechanism for the increased risk of pancreatitis \[[@pone.0233388.ref012]\]. However, not every patient can tolerate dilatation-induced pain for more than 5 minutes. In our hospital, the EPBD or EPLBD (balloon size \>10mm) was stopped when an adequate orifice was opened without active bleeding. In addition, in patients receiving EPLBD, there have been no studies investigating the association of balloon dilation time with PEP. Therefore, in this study, we aimed to investigate the effect of the balloon dilation time on the efficacy and complications of EPBD or EPLBD in the removal of bile duct stones.

Methods {#sec006}
=======

Patients {#sec007}
--------

Between November 2010 and October 2012, 198 patients who were admitted to Taipei Veterans General Hospital due to CBD stones and treated by EPBD/EPLBD were retrospectively reviewed. The diagnosis of CBD stone was made by an abdominal sonogram, computed tomography (CT) scan, or magnetic resonance cholangiopancreatography (MRCP). The Ethical Review Committee of the Taipei Veterans General Hospital approved this study.

Endoscopic papillary balloon dilation {#sec008}
-------------------------------------

The EPBD procedure was performed by three experienced endoscopists (KCL, JCL, and TSC, \> 200 procedures/year) via a duodenoscope (Olympus, JF260V). The experienced endoscopist evaluated the papilla first. In general, we used a cannula (Olympus, StarTipV, PR-V418Q) first (n = 152). If a small orifice of the papilla was noted, we used a taper cannula (Olympus, StarTipV, PR-V220Q) (n = 46). If the cannula and taper cannula both failed, we tried a guidewire-assisted cannulation (Olympus, VisiGlide2, G-26---2545S). None of these patients received precuts due to difficult cannulations. A difficult cannulation was defined after 5 minutes or five attempts, or more than one pancreatic cannulation (n = 54, 27.3%) \[[@pone.0233388.ref015]\]. We used CRE^™^ Balloon Dilatation Catheters (Boston scientific) for papillary dilatation, the balloon sizes ranged 8-15mm. The termination of the dilatation was decided subjectively according to an adequate biliary orifice opened without bleeding, and the dilatation time was recorded by a timer. After papillary dilatation, the CBD stone was extracted by the single-use retrieval basket (Olympus, TetraCatchV, FG-V422PR) or the balloon extractor (CONMED, DURAglide3 stone balloon) with/without lithotripsy (Olympus, LithoCrushV and lithotripsy handle MAJ-441).

Data collection {#sec009}
---------------

Medical records were reviewed for data collection. The following data were collected: (1) patients characteristics, such as age, sex, underlying diseases, and previous abdominal surgery history; (2) laboratory data, such as complete blood cell counts, international normalized ratio (INR), and serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TB), alkaline phosphatase (Alk-P), γ-glutamyl-transferase (γ-GT), blood urea nitrogen (BUN), creatinine, measured by Rochi/Hitachi Modular Analytics Systems (Roche Diagnostics GmbH, Mannheim, Germany); (3) findings during the procedure, such as maximum CBD diameter, CBD stone size, pancreatic duct cannulation, balloon dilatation time, and the tool used for the stone removal (basket or extraction balloon); (4) procedure-related complications and mortality; and (5) in hospital mortality and causes of mortality.

Statistical analysis {#sec010}
--------------------

All statistical analyses were performed using the SPSS 17.0 for Windows (SPSS. Inc., Chicago, IL, USA). Continuous variables were presented as mean ± standard deviation. Logistic regression was used to determine the effects of variables on post ERCP pancreatitis. Only variables with p-values proximal to 0.1 in the univariate analysis were selected for the multivariate analysis. The effects of categorical variables on the outcomes were tested by the chi-square test. A two-tailed p value \< 0.05 was considered to be significant.

Results {#sec011}
=======

Basic characteristics {#sec012}
---------------------

In total, 198 patients with CBD stones were admitted to our hospital and treated by EPBD. The mean age was 71.2±15.0 years (range, 25--97 years), and 128 (64.6%) patients were male. We separated the patients into three groups according to dilatation duration (t, minutes) (Group A, t\< 3; Group B, 3≤ t \< 5; Group C: t ≥ 5).

The basic characteristics of the three groups are shown in [Table 1](#pone.0233388.t001){ref-type="table"}. There was no significant difference in age, sex, body mass index, and underlying comorbidities. The clinical conditions before EPBD- including vital signs, blood cell counts, renal function, liver function, and biliary tract profile were not significantly different.

10.1371/journal.pone.0233388.t001

###### Basic characteristics of the patients.

![](pone.0233388.t001){#pone.0233388.t001g}

  Group                        A (t\< 3)           B (3≦ t \< 5)      C (t ≧ 5)          P
  ---------------------------- ------------------- ------------------ ------------------ ------
  N (number)                   30                  97                 71                 
  Age (year-old)               69.37±15.3          69.6±15.8          74.3±13.4          .105
  Sex (M)                      17 (56.7)           68 (70.1)          43 (60.6)          .270
  BMI                          24.9±3.9            23.3±3.5           23.9±4.0           .176
  BW (kg)                      62.8±13.0           61.8±10.7          62.6±12.2          .869
  Comorbidity                                                                            
  CV                           17 (56.7)           49 (50.5)          48 (67.6)          .086
  CM                           4 (13.3)            8 (8.2)            2 (2.8)            .139
  Neurology                    6 (20.0)            13 (13.4)          15 (21.1)          .383
  DM                           8 (26.7)            16 (16.5)          17 (23.9)          .341
  Nephrology                   3 (10.0)            6 (6.2)            5 (7.0)            .776
  Malignancy                   3 (10.0)            10 (10.3)          13 (18.3)          .272
  SBP (mmHg)                   139.5±20.2          131.3±26.4         139.2±29.5         .114
  BT (°C)                      36.8±0.8            37.0±1.1           37.0±1.2           .806
  HR (/min)                    86.5±18.7           82.5±19.9          84.4±18.3          .588
  RR (/min)                    19.1±2.2            19.0±1.7           19.8±6.8           .481
  WBC (/cumm)                  9462.3±4561.7       10634.4±6290.4     9522.8±5135.6      .376
  Hb (g/dL)                    12.6±2.2            12.9±1.5           12.7±1.8           .672
  PLT (/cumm)                  219285.7±111629.6   203684.2±71627.2   189676.1±77174.0   .230
  INR                          1.1±0.1             1.1±0.1            1.1±0.1            .629
  ALT (U/L)                    170.0±302.4         228.1±229.4        173.5±174.3        .235
  AST (U/L)                    211.9±580.3         251.1±268.6        229.5±263.2        .855
  BUN (mg/dL)                  18.7±9.1            17.6±8.2           19.0±11.4          .671
  Cr (mg/dL)                   1.1±0.6             1.2±0.6            1.3±1.6            .587
  ALP (U/L)                    212.1±172.3         224.7±149.3        226.8±174.5        .919
  rGT (U/L)                    321.6±340.9         373.2±298.8        331.6±355.6        .653
  Amy (U/L)                    655.9±953.4         570.0±955.0        993.6±1538.4       .372
  Tbili (mg/dL)                3.2±2.7             3.6±3.8            3.1±2.7            .617
  CRP (mg/dL)                  7.9±8.6             6.0±6.6            5.2±5.6            .267
  Antiplatelet                 4 (13.3)            13 (13.4)          10 (14.1)          .991
  Anticoagulant                1 (3.3)             0 (0)              2 (2.8)            .227
  Bile culture                 1 (3.3)             12(12.4)           9 (12.7)           .338
  Blood culture                2 (6.7)             16(16.5)           8 (11.3)           .320
  PTCD/PTGBD                   1(3.3)              9 (9.3)            7 (9.9)            .389
  Previous Abdominal Surgery   8 (26.7)            28 (28.9)          24 (33.8)          .707
  Previous EST                 0 (0)               4 (4.1)            4 (5.6)            .421
  Previous EPBD                0 (0)               1 (1.0)            3 (4.2)            .241

t: endoscopic papillary balloon dilatation duration time, N: number, BMI: body mass index, BW: body weight, CV: cardiovascular, CM: chest, DM: diabetes mellitus, SBP: systolic blood pressure, BT: body temperature, HR: heart rate, RR: respiratory rate, WBC: white blood cell count, Hb: hemoglobin, PLT: platelet, INR: international normalized ratio, ALT: alanine aminotransferase, AST: aspartate aminotransferase, BUN: blood urea nitrogen, Cr: creatinine, ALP: alkaline phosphatase, rGT: gamma-glutamyl transpeptidase, Amy: amylase, Tbili: total bilirubin, CRP: c-reactive protein, BD: bile duct, CBD: common bile duct, PTCD: percutaneous transhepatic cholangiography and drainage, PTGBD: percutaneous transhepatic gallbladder drainage, EST: endoscopic sphincterotomy, EPBD: endoscopic papillary balloon dilatation.

Dilatation time was associated with CBD stone size {#sec013}
--------------------------------------------------

The findings during the EPBD procedure are shown in [Table 2](#pone.0233388.t002){ref-type="table"}. There were no significant differences in the maximum CBD diameter, proportion of juxtapapillary diverticulum, and lithotripsy used between the three groups. However, patients in Group C had a larger CBD stone size (9.1±4.2 vs. 8.2±3.8 vs. 11.0±5.7mm, p = 0.003) and higher proportion of larger CBD stone (stones ≥ 10mm: 33.3 vs. 26.8 vs. 53.5%, p = 0.01). These results imply that bigger CBD stones need more dilatation time for EPBD to stop bleeding and ensure orifice opening.

10.1371/journal.pone.0233388.t002

###### Findings during procedure.

![](pone.0233388.t002){#pone.0233388.t002g}

  Group                       A (t\< 3)   B (3≦ t \< 5)   C (t ≧ 5)   P
  --------------------------- ----------- --------------- ----------- ------
  N (number)                  30          97              71          
  CBD stone \> = 10mm         10 (33.3)   26 (26.8)       38 (53.5)   .010
  Maximum CBD diameter (mm)   15.1±5.0    14.8±4.8        16.2±5.1    .175
  CBD stone size (mm)         9.1±4.2     8.2±3.8         11.0±5.7    .003
  JPD                         10 (33.3)   41 (42.3)       35 (49.3)   .318
  Pus                         2(6.7)      3 (3.1)         4(5.6)      .632
  Sludge                      5 (16.7)    26(26.8)        19(26.8)    .481
  Balloon size (mm)                                                   .108
  8                           11          29              12          
  10                          15          46              32          
  11                          0           3               4           
  12                          2           17              16          
  14                          1           2               6           
  15                          1           0               1           
  EPLBD (\>10mm)              4 (13.3%)   22 (22.7%)      27 (38%)    .017
  Complete removal            30 (100%)   97 (100%)       71 (100%)   
  Extraction Balloon          10(33.3)    36(37.1)        24(33.8)    .876
  Retrieval Basket            15 (50.0)   56 (57.7)       47 (66.2)   .354
  Precut                      0 (0)       0 (0)           0(0)        \-
  Schendra                    0 (0)       0 (0)           0(0)        \-
  Lithotripsy                 0(0)        2 (2.1)         5 (7.0)     .118

CBD: common bile duct, JPD: juxtapapillary diverticulum, EPLBD: endoscopic papillary large balloon dilatation.

EPBD complications {#sec014}
------------------

[Table 3](#pone.0233388.t003){ref-type="table"} shows the complications after EPBD. Overall, there were no significant differences in the PEP rate between the three groups (13.3% vs. 3.1% vs. 4.2%, p = 0.075). However, the subgroup analysis showed that the group A patients had a significant higher PEP rate than the group B patients (13.3% vs. 3.1%, p = 0.032). There were no perforations or deaths that occurred in the three groups. The bleeding rate, post EPBD biliary tract infection, and aspiration pneumonia were not significantly different. In addition, there was no difference in biliary tract infection when compared the Group A (n = 0) with the Groups B and C together (n = 10) (p = 0.170).

10.1371/journal.pone.0233388.t003

###### Post endoscopic papillary balloon dilatation complication.

![](pone.0233388.t003){#pone.0233388.t003g}

  Group                  A (t\< 3)                                      B (3≦ t \< 5)                                 C (t ≧ 5)   P
  ---------------------- ---------------------------------------------- --------------------------------------------- ----------- ------
  N (number)             30                                             97                                            71          
  Bleeding               0 (0)                                          2 (2.1)                                       0 (0)       .349
  Perforation            0 (0)                                          0(0)                                          0(0)        \-
  Pancreatitis           4(13.3)[\*](#t003fn001){ref-type="table-fn"}   3(3.1)[\*](#t003fn001){ref-type="table-fn"}   3(4.2)      .075
  BTI                    0(0)                                           4 (4.1)                                       6 (8.5)     .175
  Aspiration Pneumonia   0 (0)                                          0 (0)                                         1 (1.4)     .407
  In hospital death      0(0)                                           0 (0)                                         0 (0)       \-

\* P = 0.032 between Group A and B.

BTI: biliary tract infection.

Post-ERCP pancreatitis rate {#sec015}
---------------------------

We further analyzed the risk factor of post-EPBD pancreatitis ([Table 4](#pone.0233388.t004){ref-type="table"}). In the univariate analysis, an age ≤ 75 years (p = 0.052), female (p = 0.094), total bilirubin ≤1.2 mg/dL (p = 0.096), CBD diameter \< 10 mm (p = 0.051), difficult cannulation (p = 0.098), and dilatation duration \< 3minutes (p = 0.049) were possible risk factors of PEP. A further multivariate analysis showed that age ≤ 75 years (OR, 5.006; p = 0.057), CBD \< 10 mm (OR, 5.332; p = 0.034), and dilatation duration \< 3 minutes (OR, 4.942; p = 0.027) were still independent risk factors of post-EPBD pancreatitis. In 53 patients who received EPLBD, the dilatation time for a minimum of three minutes did not increase the PEP rate (0% vs. 4.5% vs. 0%, p = 0.488) ([Table 5](#pone.0233388.t005){ref-type="table"}).

10.1371/journal.pone.0233388.t004

###### Univariate and multivariate analysis of post ERCP pancreatitis.

![](pone.0233388.t004){#pone.0233388.t004g}

                                                               Univariate Analysis   Multivariate Analysis                                 
  ------------------------------------------------------------ --------------------- ----------------------- ---------- ---------- ------- ---------------
  Age (≤75-year-old)                                           8/10 (80.0%)          91/188 (48.4%)          **.052**   **.057**   5.006   0.954--26.286
  Sex (male)                                                   4/10 (40.0%)          124/188 (66.0%)         **.094**   NA                 
  Total bilirubin (≤ 1.2 mg/dL)                                5/10 (50.0%)          48/188 (25.5%)          **.096**   NA                 
  CBD \< 10mm                                                  3/10 (30.0%)          19/188 (10.1%)          **.051**   **.034**   5.332   1.134--25.058
  Pancreatic duct cannulation                                  3/10 (30.0%)          36/188 (19.1%)          .401       NA                 
  JPD (+)                                                      3/10 (30.0%)          83/188 (44.1%)          .379       NA                 
  Balloon size                                                                                               .577                          
  EPLBD (\>10mm)                                               1/10 (10.0%)          52/188 (27.7%)          .267       NA                 
  Difficult cannulation[\*](#t004fn002){ref-type="table-fn"}   5/10 (50.0%)          49/188 (26.1%)          **.098**   NA                 
  CBD stone \< 10mm                                            7/10 (70.0%)          92/188 (48.9%)          .201       NA                 
  Lithotripsy (+)                                              0/10 (0.0%)           7/188 (3.7%)            .534                          
  Dilatation \< 3min                                           4/10 (40.0%)          26/188 (13.9%)          **.049**   **.027**   4.942   1.194--20.447
  Dilatation \< 5min                                           7/10 (70.0%)          120/188 (63.8%)         .692       NA                 
  Time                                                                                                       .332       NA                 

ERCP: endoscopic retrograde cholangiopancreatography, PEP: post ERCP pancreatitis, OR: odds ratio, CI: Confidence interval, NA: not available, NS: not significant, CBD: common bile duct, JPD: juxtapapillary diverticulum, EPLBD: endoscopic papillary large balloon dilatation

\*: cannulation attempts of duration \> 5 minutes, \> 5 attempts, or 2 pancreatic guidewire passages.

10.1371/journal.pone.0233388.t005

###### Post endoscopic papillary balloon dilatation complication in EPLBD patients.

![](pone.0233388.t005){#pone.0233388.t005g}

  Group                  A (t\< 3)   B (3≦ t \< 5)   C (t ≧ 5)   P
  ---------------------- ----------- --------------- ----------- ------
  N (number)             4           22              27          .017
  Bleeding               0 (0)       1 (4.5)         0 (0)       .488
  Perforation            0 (0)       0 (0)           0 (0)       \-
  Pancreatitis           0 (0)       1 (4.5)         0 (0)       .488
  BTI                    0 (0)       2 (9.1)         1 (3.7)     .632
  Aspiration Pneumonia   0 (0)       0 (0)           0 (0)       \-
  In hospital death      0 (0)       0 (0)           0 (0)       \-

EPLBD: Endoscopic papillary large balloon dilatation; BTI: Biliary tract infection.

Discussion {#sec016}
==========

The current consensus suggests EPBD as an alternative to EST for extracting CBD stones, especially in the presence of coagulopathy or altered anatomy \[[@pone.0233388.ref007]\]. However, the biggest concern of EPBD was the increased rate of post-EPBD pancreatitis \[[@pone.0233388.ref002], [@pone.0233388.ref004], [@pone.0233388.ref005], [@pone.0233388.ref009], [@pone.0233388.ref010], [@pone.0233388.ref016]\]. Previous studies have demonstrated that the incidence of post-EPBD pancreatitis was 7.4--15.4% \[[@pone.0233388.ref002], [@pone.0233388.ref004], [@pone.0233388.ref005], [@pone.0233388.ref009]\]. The incidence of PEP in our study is 6.6%, which was better than that of previous studies. Liao et al. first demonstrated that a 5-minute EPBD reduces the risk of pancreatitis compared with the conventional 1-minute EPBD (4.8% vs. 15.1%, p = 0.038) \[[@pone.0233388.ref012]\]. Further systematic reviews showed that the duration of EPBD was inversely associated with pancreatitis risk \[[@pone.0233388.ref011]\]. Current clinical guideline suggests a EPBD duration of at least 2 minutes \[[@pone.0233388.ref007]\]. The mechanism of pancreatitis was thought to involve the compartment syndrome from the post-EPBD hemorrhage/edema of an uncut sphincter of Oddi \[[@pone.0233388.ref012], [@pone.0233388.ref017]\]. If the theory was true, the critical point of pancreatitis should be whether EPBD cause loosened sphincter ampullae, not the duration of the balloon dilatation. Our results showed that a dilatation time of at least 3 minutes with an adequate orifice opening did not increase the incidence of post-EPBD pancreatitis. Younger age was well-known as a risk factor of PEP \[[@pone.0233388.ref018]\], and post-EPBD compartment syndrome may explain why small CBD diameter was also an independent risk factor of pancreatitis.

The incidence of PEP in patients with EPLBD patients was 0.8--11.2% in previous studies \[[@pone.0233388.ref013], [@pone.0233388.ref014], [@pone.0233388.ref019]\]. However, none of the previous studies discussed the adequate duration of dilatation time in patients with EPLBD. The PEP incidence in patients with EPLBD was 1.9% in our study. The PEP rate were not significantly different among the three groups. All of our patients with EPLBD had their stones removed successfully, and EML was used in six of the patients (11.3%). Our results demonstrated that at least 3 minutes of dilatation duration may be enough for patients with EPLBD.

Recent studies have proven that prophylactic pancreatic stent placement had a significant reduction in incidence and severity of PEP, and pancreatic stent placement is recommended in patients who are at a high risk for PEP \[[@pone.0233388.ref020], [@pone.0233388.ref021]\]. In our study, no repeated inadvertent PD cannulation occurred, so we did not place any prophylactic stents in our patients. Non-steroidal anti-inflammatory drugs (NSAIDs) have also been shown to significantly reduce the incidence and severity of PEP \[[@pone.0233388.ref022]--[@pone.0233388.ref024]\]. Aggressive lactated Ringer's (LR) hydration is thought to prevent further injury to the pancreas from microvascular hypoperfusion and activate pancreatic enzymes \[[@pone.0233388.ref025]\]. Our data was collected before these promising studies, so rectal NSAIDs or LR solution were not administered to patients in our study for PEP prevention. However, our PEP incidence was not higher than current studies. Whether longer EPBD duration plus pancreatic stent placement, rectal NSAIDs, and LR solution hydration would further decrease the PEP incidence is interesting and warrants additional investigation.

With respect of successful stone removal, Liu et al. analyzed 10 randomized control trials (RCTs), and demonstrated that EPBD has equivalently great success for complete stone removal to EST \[[@pone.0233388.ref005]\]. Zhao et al. reviewed 14 RCTs and showed that EPBD decreased the overall clearance of stones compared to EST \[[@pone.0233388.ref010]\]. It is generally acknowledged that EPBD is less likely to remove large CBD stone. In our study, we did not exclude the large CBD stones, and the proportion of large CBD stone was about one third (CBD stone ≥ 10mm, n = 74, 37.4%). The successful stone removal rate was 100%, and the utility of EML was 3.5% (n = 7). Although there was a higher proportion of large CBD stones in patients in group C, the successful stone removal rate did not decrease. Our study showed that large CBD stones may increase the duration of EPBD, but did not decrease the clearance of CBD stones. The results were consistent with those reported by Liu et al.

Additionally, a previous meta-analysis showed that the post-EPBD bleeding rate was less than 1% \[[@pone.0233388.ref010]\]. The post-EPBD bleeding rate in our study was 1%, and there were no significant differences among the three groups. Furthermore, there were no procedure related perforations that occurred in our study, similar with that of a previous meta-analysis \[[@pone.0233388.ref005]\].

There were some limitations to our study. Our study was not a randomized control trial. There may be some selection bias in the study. The time of EPBD was not standardized but was the choice of the endoscopist, this may also cause bias. It is also not current standard not to use a guidewire for primary cannulation nowadays. However, the relatively low rate of PEP reflected the acceptable experience of the endoscopist performing biliary cannulation without using a guidewire at that time. In addition, our data were collected during the period when use of NSAIDs or LR was still debatable for PEP prevention, thus, only the patients from 2010 to 2012 when no rectal NSAIDs or LR solution hydration use in our hospital were included. It is interesting to investigate whether dilatation time could further affect the occurrence of PEP in the period when rectal NSAIDs was frequently used in high risk PEP patients. Further studies are still needed to determine the adequate balloon dilatation duration.

Conclusions {#sec017}
===========

An EPBD duration of more than 3 minutes with adequate orifice opened by an experienced endoscopist may be enough for PEP prevention. A small CBD diameter, young age and shorter dilatation duration could cause more PEP.

We would like to acknowledge the assistance of Mr. Dong-Ming Liao.

EPBD

:   Endoscopic papillary balloon dilatation

PEP

:   post endoscopic retrograde cholangiopancreatography pancreatitis

ERCP

:   endoscopic retrograde cholangiopancreatography

CBD

:   common bile duct

EST

:   endoscopic sphincterotomy

EML

:   endoscopic mechanical lithotripsy

CT

:   computed tomography

MRCP

:   magnetic resonance cholangiopancreatography
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Reviewer \#1: Yes

Reviewer \#2: I Don\'t Know
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3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.
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4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes
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5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: 1. Can they give information on size of balloons used for papillary dilation (what was size in large balloon dilation).

2\. Grammatical correction \"systematic\" instead of \"systemic\" in the discussion, 8th line

3\. Information on complete stone removal on first attempt or repeat ERCP\'s were needed.

Reviewer \#2: Kuei-Chuan Lee et al. present in their manuscript "Endoscopic Papillary Balloon Dilatation less than three minutes for biliary Stone Removal Increases the Risk of Post-ERCP-Pancreatitis" interesting data from a retrospective single centre observational study on 198 patients (11/2010-10/2012). The main finding was that in patients that underwent Endoscopic Papillary Balloon Dilatation (EPBD) for stone removal, dilatation duration \< 3 minutes, lower CBD diameter and younger age were in a multivariate analysis independently associated with Post-ERCP-Pancreatitis (PEP).

As the authors have mentioned in their manuscript, a number of previous studies have already shown that the duration of EPBD was inversely associated with PEP; therefore, clinical guidelines already suggest an EPBD duration of at least 2 minutes.

The authors furthermore emphasize that no studies investigated so far, the impact of large balloon dilatation (EPLBD) on PEP. Nevertheless, the findings presented here are indeed not surprising but rather confirm previous studies.

It is unclear to me, why the authors choose the time intervals at 3min and 5min dilatation time to build the three groups that they compared? Why not 2min or 4 min? Was there an ROC-analysis performed to identify the optimal discriminatory time point?

I also wonder why only patients between 2010 and 2012 were included. For the endpoint PEP a long follow-up is not needed and therefore there is no obvoious reason not to include also patients from the years 2013-2018. This would also allow to include protective stenting and NSAIDs as protective factors.

Furthermore, in the Methods it is not mentioned which balloons and which sizes of balloons were used for EPBD and EPLBD. This essential information must be given.

Balloon Diameter (if different balloons were used) and also mechanical lithotripsy should additionally be included in the analysis of risk factors (table 4).

Minor limitations are the retrospective study design with a possible BIAS since the time of EPBD was not standardized but was the choice of the endoscopist.

It is also not current standard anymore not to use a guidewire for primary cannulation. However, the relatively low rate of PEP reflect the skills and experience of the endoscopist performing biliary cannulation without using a guidewire.

In Table 2 percentages should also be given for EPLBD.

An interesting but not significant finding was that no biliary tract infection was found in group A but 4.1% in group B and 8.5% in group C. If Group A would be compared with Group B and C together was the difference than statistically significant?
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6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.
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Reviewer \#1:

1\. Can they give information on size of balloons used for papillary dilation (what was size in large balloon dilation).

Reply: Thanks for your comments. We added the information in the revised table2. EPLBD was defined as balloon size more than 10mm (revised table 2).

2\. Grammatical correction \"systematic\" instead of \"systemic\" in the discussion, 8th line

Reply: Thanks for your kind comment. We revised the grammatical error as your suggestion. (page 12, 1st line)

3\. Information on complete stone removal on first attempt or repeat ERCP\'s were needed.

Reply: Thanks for your comments. Actually, all stones were removed successfully on first attempt and no repeat ERCP was done during the follow up period. The information was added in the revised table 2.

Reviewer \#2:

Kuei-Chuan Lee et al. present in their manuscript "Endoscopic Papillary Balloon Dilatation less than three minutes for biliary Stone Removal Increases the Risk of Post-ERCP-Pancreatitis" interesting data from a retrospective single centre observational study on 198 patients (11/2010-10/2012). The main finding was that in patients that underwent Endoscopic Papillary Balloon Dilatation (EPBD) for stone removal, dilatation duration \< 3 minutes, lower CBD diameter and younger age were in a multivariate analysis independently associated with Post-ERCP-Pancreatitis (PEP).

As the authors have mentioned in their manuscript, a number of previous studies have already shown that the duration of EPBD was inversely associated with PEP; therefore, clinical guidelines already suggest an EPBD duration of at least 2 minutes.

The authors furthermore emphasize that no studies investigated so far, the impact of large balloon dilatation (EPLBD) on PEP. Nevertheless, the findings presented here are indeed not surprising but rather confirm previous studies.

It is unclear to me, why the authors choose the time intervals at 3min and 5min dilatation time to build the three groups that they compared? Why not 2min or 4 min? Was there an ROC-analysis performed to identify the optimal discriminatory time point?

Reply: Thanks for your comments. The time point was not set by ROC analysis. However, a randomized trial by Liao et al. found that the risk of PEP was lower with a 5min EPBD as compared with those with a 1min EPBD (Gastrointest Endosc. 2010;72(6):1154-62). Therefore, we firstly chose 5min as a discriminatory point. Then we found that the mean of dilatation duration was 208.26±4.54 seconds, and the median was 210 seconds among the patients who received balloon dilatation duration less than 5 minutes (n= 127). For the convenience in daily practical use, we then chose 3min as another discriminatory point, which near the mean or median value in the patients receiving balloon dilatation time less than 5min. Finally, the time intervals at 3min and 5min were chosen.

I also wonder why only patients between 2010 and 2012 were included. For the endpoint PEP a long follow-up is not needed and therefore there is no obvoious reason not to include also patients from the years 2013-2018. This would also allow to include protective stenting and NSAIDs as protective factors.

Reply: Thanks for your comments. We totally agree that protective stenting and rectal NSAIDs are important protective factors for PEP nowadays. However, during the period (2014-2016) when we retrospectively started to collect the data of patients receiving EPBD in our hospital, the use of rectal NSAIDs and stenting were still debatable. Therefore, we only chose the patients between 2010 and 2012 when no rectal NSAIDs or stenting was used in our ERCP room. Actually, we are interested in whether dilatation time could further affect the occurrence of PEP in another time period (2013-2018) when rectal NSAIDs was frequently used in high risk PEP patients in our hospital, future study will be initiated. (page 14, line 18)

Furthermore, in the Methods it is not mentioned which balloons and which sizes of balloons were used for EPBD and EPLBD. This essential information must be given.

Balloon Diameter (if different balloons were used) and also mechanical lithotripsy should additionally be included in the analysis of risk factors (table 4).

Reply: Thanks for your important suggestions. We had added information of balloons and size in the revised method (page 7, line 12) and Table 2. Mechanical lithotripsy had no significantly predictive value in univariate analysis (revised Table 4).

Minor limitations are the retrospective study design with a possible BIAS since the time of EPBD was not standardized but was the choice of the endoscopist.

It is also not current standard anymore not to use a guidewire for primary cannulation. However, the relatively low rate of PEP reflect the skills and experience of the endoscopist performing biliary cannulation without using a guidewire.

Reply: Thanks for your comments. We added these comments as study limitations in the revised discussion (page 14, line 14).

In Table 2 percentages should also be given for EPLBD.

Reply: Thanks for your comment, we had revised that in the Table 2 as your suggestion.

An interesting but not significant finding was that no biliary tract infection was found in group A but 4.1% in group B and 8.5% in group C. If Group A would be compared with Group B and C together was the difference than statistically significant?

Reply: We had analyzed that as your suggestion. However, there was no difference in biliary tract infection when compared the Group A (n=0) with the Groups B and C together (n=10) (p=0.170). (page 10, line 15).

###### 

Submitted filename: Respone to Reviewers.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0233388.r003

Decision Letter 1

Strnad

Pavel

Academic Editor

© 2020 Pavel Strnad

2020

Pavel Strnad

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

5 May 2020

Endoscopic Papillary Balloon Dilatation less than Three Minutes for Biliary Stone Removal Increases the Risk of Post-ERCP Pancreatitis

PONE-D-19-32543R1

Dear Dr. Lee,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.
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2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.
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5\. Is the manuscript presented in an intelligible fashion and written in standard English?
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Dear Dr. Lee:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.
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